Passage Bio (PASG) Competitors $0.38 -0.03 (-7.79%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$0.38 +0.00 (+0.26%) As of 03/28/2025 05:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PASG vs. MGNX, VIRI, FTLF, VXRT, EDIT, ELUT, RENB, TLSA, ADVM, and COYAShould you be buying Passage Bio stock or one of its competitors? The main competitors of Passage Bio include MacroGenics (MGNX), Virios Therapeutics (VIRI), FitLife Brands (FTLF), Vaxart (VXRT), Editas Medicine (EDIT), Elutia (ELUT), Renovaro (RENB), Tiziana Life Sciences (TLSA), Adverum Biotechnologies (ADVM), and Coya Therapeutics (COYA). These companies are all part of the "pharmaceutical products" industry. Passage Bio vs. MacroGenics Virios Therapeutics FitLife Brands Vaxart Editas Medicine Elutia Renovaro Tiziana Life Sciences Adverum Biotechnologies Coya Therapeutics MacroGenics (NASDAQ:MGNX) and Passage Bio (NASDAQ:PASG) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, community ranking, institutional ownership, valuation, risk, analyst recommendations and earnings. Does the media refer more to MGNX or PASG? In the previous week, MacroGenics had 9 more articles in the media than Passage Bio. MarketBeat recorded 10 mentions for MacroGenics and 1 mentions for Passage Bio. Passage Bio's average media sentiment score of 1.87 beat MacroGenics' score of 0.44 indicating that Passage Bio is being referred to more favorably in the news media. Company Overall Sentiment MacroGenics Neutral Passage Bio Very Positive Do institutionals and insiders believe in MGNX or PASG? 96.9% of MacroGenics shares are owned by institutional investors. Comparatively, 53.5% of Passage Bio shares are owned by institutional investors. 11.3% of MacroGenics shares are owned by insiders. Comparatively, 4.3% of Passage Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is MGNX or PASG more profitable? Passage Bio has a net margin of 0.00% compared to MacroGenics' net margin of -69.07%. Passage Bio's return on equity of -72.53% beat MacroGenics' return on equity.Company Net Margins Return on Equity Return on Assets MacroGenics-69.07% -89.42% -38.57% Passage Bio N/A -72.53%-52.10% Do analysts rate MGNX or PASG? MacroGenics currently has a consensus price target of $7.38, indicating a potential upside of 485.32%. Passage Bio has a consensus price target of $7.50, indicating a potential upside of 1,868.50%. Given Passage Bio's stronger consensus rating and higher probable upside, analysts clearly believe Passage Bio is more favorable than MacroGenics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MacroGenics 0 Sell rating(s) 8 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.36Passage Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, MGNX or PASG? MacroGenics has a beta of 2.12, meaning that its stock price is 112% more volatile than the S&P 500. Comparatively, Passage Bio has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500. Does the MarketBeat Community prefer MGNX or PASG? MacroGenics received 373 more outperform votes than Passage Bio when rated by MarketBeat users. However, 68.83% of users gave Passage Bio an outperform vote while only 62.10% of users gave MacroGenics an outperform vote. CompanyUnderperformOutperformMacroGenicsOutperform Votes42662.10% Underperform Votes26037.90% Passage BioOutperform Votes5368.83% Underperform Votes2431.17% Which has better valuation & earnings, MGNX or PASG? MacroGenics has higher revenue and earnings than Passage Bio. MacroGenics is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMacroGenics$148.34M0.54-$9.06M-$1.08-1.17Passage BioN/AN/A-$102.06M-$1.07-0.36 SummaryMacroGenics and Passage Bio tied by winning 9 of the 18 factors compared between the two stocks. Remove Ads Get Passage Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for PASG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PASG vs. The Competition Export to ExcelMetricPassage BioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.68M$3.03B$5.63B$7.84BDividend YieldN/A1.55%5.33%4.01%P/E Ratio-0.3330.4523.5818.74Price / SalesN/A431.82388.2390.77Price / CashN/A168.6838.1734.64Price / Book0.193.926.894.23Net Income-$102.06M-$71.95M$3.20B$247.47M7 Day Performance-23.97%-5.68%-3.06%-2.29%1 Month Performance-26.45%-12.09%1.51%-5.81%1 Year Performance-71.78%-27.90%9.37%-0.96% Passage Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PASGPassage Bio3.2354 of 5 stars$0.38-7.8%$7.50+1,868.5%-71.8%$23.68MN/A-0.33130Positive NewsGap DownMGNXMacroGenics3.8872 of 5 stars$1.96-2.0%$7.63+289.0%-91.4%$123.02M$148.34M-1.24430Analyst ForecastAnalyst RevisionVIRIVirios Therapeutics0.3916 of 5 stars$6.33-7.3%$3.00-52.6%+1,077.2%$121.90MN/A-23.445News CoverageGap UpFTLFFitLife Brands4.477 of 5 stars$13.23-1.9%$20.50+55.0%+5.9%$121.85M$62.76M15.6620Earnings ReportShort Interest ↓Analyst RevisionNews CoverageVXRTVaxart2.2044 of 5 stars$0.51-0.7%$4.00+680.3%-67.6%$116.61M$28.70M-1.25120Analyst ForecastAnalyst RevisionNews CoverageEDITEditas Medicine4.0729 of 5 stars$1.39+6.1%$6.83+391.6%-83.2%$115.34M$32.31M-0.54230Analyst RevisionELUTElutia3.9271 of 5 stars$2.81-3.8%$9.00+220.3%-16.2%$114.47M$24.38M-1.08180Short Interest ↓News CoveragePositive NewsRENBRenovaro1.0624 of 5 stars$0.72+2.6%N/A-78.1%$114.04MN/A-0.7720Positive NewsGap DownTLSATiziana Life Sciences0.4827 of 5 stars$1.08-2.7%N/A+146.7%$113.83MN/A0.008Short Interest ↑ADVMAdverum Biotechnologies4.4055 of 5 stars$5.40+5.9%$27.83+415.4%-67.4%$112.33M$1M-0.90190Insider TradeNews CoveragePositive NewsCOYACoya Therapeutics2.0354 of 5 stars$6.65-0.4%$17.00+155.6%-33.9%$111.22M$3.55M-10.236Analyst ForecastAnalyst RevisionNews Coverage Remove Ads Related Companies and Tools Related Companies MGNX Alternatives VIRI Alternatives FTLF Alternatives VXRT Alternatives EDIT Alternatives ELUT Alternatives RENB Alternatives TLSA Alternatives ADVM Alternatives COYA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PASG) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredWall Street’s “AI Oracle” Reveals Next Big Tech PlayA tiny American tech company could be at the center of the next big AI breakthrough. Wall Street's "AI Orac...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Passage Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Passage Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
